Khalid M Kamal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9225530/publications.pdf

Version: 2024-02-01

28	521	12	22
papers	citations	h-index	g-index
28	28	28	614
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Economic Impact of Ambulatory Clinical Pharmacists in an Advanced Heart Failure Clinic. Annals of Pharmacotherapy, 2022, 56, 1203-1209.	1.9	1
2	The Relationship between Knowledge, Attitudes, and Practices of Community Pharmacists Regarding Persons with Substance use Disorders. Substance Abuse, 2021, 42, 630-637.	2.3	12
3	Patient Satisfaction with Substance Use Disorder Rehabilitation Services: a Qualitative Study. Journal of Behavioral Health Services and Research, 2021, 48, 213-239.	1.4	2
4	Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database. Journal of Drug Assessment, 2021, 10, 62-67.	2,2	15
5	Description of pharmacists' reported interventions to prevent prescribing errors among in hospital inpatients: a cross sectional retrospective study. BMC Health Services Research, 2021, 21, 432.	2.2	2
6	Pharmacist Views Regarding the Prescription Opioid Epidemic. Substance Use and Misuse, 2021, 56, 1-10.	1.4	7
7	Barriers and facilitators to diabetes self-management in a primary care setting – Patient perspectives. Research in Social and Administrative Pharmacy, 2019, 15, 279-286.	3.0	13
8	Factors that facilitate reporting of adverse drug reactions by pharmacists in Saudi Arabia. Expert Opinion on Drug Safety, 2019, 18, 745-752.	2.4	18
9	Barriers and facilitators to shared decision-making in oncology: a systematic review of the literature. Supportive Care in Cancer, 2019, 27, 1613-1637.	2.2	96
10	Oral antidiabetic medication adherence and glycaemic control among patients with type 2 diabetes mellitus: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open, 2019, 9, e029280.	1.9	25
11	<p>Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia</p> . Patient Preference and Adherence, 2019, Volume 13, 2111-2118.	1.8	12
12	The relationship between a cirrhosisâ€specific comorbidity scoring system and healthcare utilization patterns. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1222-1230.	2.8	0
13	Variation in prostate surgery costs and outcomes in the USA: robot-assisted versus open radical prostatectomy. Journal of Comparative Effectiveness Research, 2019, 8, 143-155.	1.4	14
14	Impact of atrial fibrillation on inpatient cost for ischemic stroke in the USA. International Journal of Stroke, 2019, 14, 159-166.	5.9	17
15	HTA Metro Map: a patient centred model for optimizing the decision making process. GMS Health Innovation and Technologies, 2019, 15, Doc02.	0.5	0
16	Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 987-997.	0.9	3
17	Hospitalization costs of cystic fibrosis in the United States: a retrospective analysis. Hospital Practice (1995), 2018, 46, 203-213.	1.0	12
18	Community pharmacists and mental illness: a survey of service provision, stigma, attitudes and beliefs. International Journal of Clinical Pharmacy, 2018, 40, 1096-1105.	2.1	34

#	Article	IF	CITATION
19	Evaluation of Primary Care Physician Chronic Pain Management Practice Patterns. Pain Physician, 2018, 21, E593-E602.	0.4	6
20	Monetary costs of multiple medication use for the treatment of individuals in recovery from chemical dependency. Addictive Behaviors, 2017, 71, 118-120.	3.0	1
21	Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 666-676.	0.9	12
22	Adherence With Therapeutic Regimens. Journal of Pharmacy Practice, 2016, 29, 138-143.	1.0	7
23	Use of electronic medical records for clinical research in the management of type 2 diabetes. Research in Social and Administrative Pharmacy, 2014, 10, 877-884.	3.0	8
24	Content Analysis of FDA Warning Letters to Manufacturers of Pharmaceuticals and Therapeutic Biologicals for Promotional Violations. Drug Information Journal, 2009, 43, 385-393.	0.5	14
25	Use ofÂtumor necrosis factor inhibitors inÂrheumatoid arthritis: aÂnational survey ofÂpracticing United States rheumatologists. Joint Bone Spine, 2006, 73, 718-724.	1.6	46
26	Alternative Decision Analysis Modeling in the Economic Evaluation of Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism, 2006, 36, 50-60.	3.4	4
27	Determinants of Adult Influenza and Pneumonia Immunization Rates. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 403-411.	1.5	82
28	Pharmacy and Immunization Services: Pharmacists' Participation and Impact. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 470-482.	1.5	58